文献速递临床试验与 GCP基础与转化研究

慈心禅团体冥想联合个体认知行为疗法治疗慢性抑郁:随机对照试验方案

Metta-based group meditation and individual cognitive behavioral therapy (MeCBT) for chronic depression: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2020-01-06

主要结局为干预后(T2)临床医生评定的抑郁症状(QIDS-C)变化,预期MeCBT组显著优于对照组。

要点

  • MeCBT为低强度、成本效益好的新型干预,融合团体慈心禅冥想与个体CBT。
  • 主要结局为T2时QIDS-C评定的抑郁症状变化,采用观察者盲法评估。
  • 干预包括8次每周团体冥想、1次半日静修及8次每两周个体CBT。

核心结论

  • 预期MeCBT组在个体CBT结束后(T2)抑郁症状较等待名单对照组显著下降。

主要发现

  • 主要结局为QIDS-C评定的抑郁症状变化,评估时间点为T0(干预前)、T1(团体冥想后)、T2(个体CBT后)及仅治疗组的T3(6个月随访)。
  • 次要结局包括自评抑郁、正念、仁慈、反刍、情绪调节、社会连接、社会功能及行为与认知回避,探索T1和T2的变化。

关键数值与推荐

  • 团体慈心禅冥想为8次每周课程加1次半日静修,随后个体CBT为8次每两周课程。

临床怎么用

  • 若验证有效,MeCBT可作为慢性抑郁的低强度、成本效益好的治疗选择,整合冥想与CBT。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Depression is a widespread disorder with severe impacts for individuals and society, especially in its chronic form. Current treatment approaches for persistent depression have focused primarily on reducing negative affect and have paid little attention to promoting positive affect. Previous studies have shown that metta meditation increases positive affect in chronically depressed patients. Results from previous trials provide evidence for the efficacy of a stand-alone metta meditation group treatment in combination with mindfulness-based approaches. Further research is needed to better understand the implementation of meditation practice into everyday life. Therefore, mindfulness and metta meditation in a group setting are combined with individual cognitive behavioral therapy (CBT) into a new, low-intensity, cost-effective treatment ("MeCBT") for chronic depression. METHODS/DESIGN: In this single-center, randomized, observer-blinded, parallel-group clinical trial we will test the efficacy of MeCBT in reducing depression compared to a wait-list control condition. Forty-eight participants in a balanced design will be allocated randomly to a treatment group or a wait-list control group. Metta-based group meditation will be offered in eight weekly sessions and one additional half-day retreat. Subsequent individual CBT will be conducted in eight fortnightly sessions. Outcome measures will be assessed at four time points: before intervention (T0); after group meditation (T1); after individual CBT (T2); and, in the treated group only, at 6-month follow-up (T3). Changes in depressive symptoms (clinician rating), assessed with the Quick Inventory of Depressive Symptoms (QIDS-C) are the primary outcome. We expect a significant decline of depressive symptoms at T2 compared to the wait-list control group. Secondary outcome measures include self-rated depression, mindfulness, benevolence, rumination, emotion regulation, social connectedness, social functioning, as well as behavioral and cognitive avoidance. We will explore changes at T1 and T2 in all these secondary outcome variables. DISCUSSION: To our knowledge this is the first study to combine a group program focusing on Metta meditation with state-of-the art individual CBT specifically tailored to chronic depression. Implications for further refinement and examination of the treatment program are discussed. TRIAL REGISTRATION: ISRCTN, ISRCTN97264476. Registered 29 March 2018 (applied on 14 December 2017)-retrospectively registered.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Frick A, Thinnes I, Stangier U, et al. Metta-based group meditation and individual cognitive behavioral therapy (MeCBT) for chronic depression: study protocol for a randomized controlled trial. Trials. 2020. PMID: 31907002. doi:10.1186/s13063-019-3815-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。